We have searched several databases including PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases and selected the randomized controlled trials comparing the efficacy of
rimegepant versus placebo for
migraine patients. This meta-analysis was conducted using the random- or fixed-effect model based on the heterogeneity.
RESULTS: Three randomized controlled trials were included in this meta-analysis. Compared with placebo in
migraine patients,
rimegepant treatment was associated with substantially improved freedom from
pain at 2 hours (odds ratio [OR], 2.10; 95% confidence interval [CI], 1.69-2.59; P < 0.00001),
pain relief at 2 hours (OR, 1.93; 95% CI, 1.65 to 2.25; P < 0.00001), freedom from the most bothersome symptom at 2 hours (OR, 1.61; 95% CI, 1.35-1.91; P < 0.00001), ability to function normally at 2 hours (OR, 1.69; 95% CI, 1.42-2.01; P < 0.00001), sustained freedom from
pain at 24 hours (OR, 2.88; 95% CI, 1.74-4.78; P < 0.0001), sustained
pain relief at 24 hours (OR, 2.31; 95% CI, 1.96-2.72; P < 0.00001), and no rescue medication (OR, 2.42; 95% CI, 2.02-2.90; P < 0.00001) but showed no obvious impact on adverse events (OR, 1.27; 95% CI, 1.01-1.60; P = 0.04).
CONCLUSIONS: